Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
121 hedge funds and large institutions have $163M invested in Orexigen Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 44 reducing their positions, and 22 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
8% less funds holding
Funds holding: 132 → 121 (-11)
30% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 44
30% less capital invested
Capital invested by funds: $234M → $163M (-$70.3M)
45% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 22
46% less call options, than puts
Call options by funds: $961K | Put options by funds: $1.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$4.77M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.47M |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
+$3.45M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.79M |
| 5 |
SIM
Spark Investment Management
New York
|
+$909K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$24.1M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.17M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.89M |
| 4 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$2.44M |
| 5 |
Renaissance Technologies
New York
|
-$2.42M |
OREX Hedge Fund Activity: Q4 2015 in Review
121 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q4 2015, worth a combined $163M — down 30% from $234M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of OREX and 12 opened new positions — a net loss of 10 holders — while 44 trimmed existing stakes and 31 added.
The largest buyer was Foresite Capital Management II, adding an estimated $4.77M. The largest seller was State Street, cutting an estimated $24.1M.
- 121 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q4 2015, down from 132 in Q3 2015.
- Funds reported $163M of Orexigen Therapeutics, Inc. stock for Q4 2015, down 30% quarter-over-quarter.
- 12 funds opened new Orexigen Therapeutics, Inc. positions in Q4 2015 and 22 closed out, a net change of -10 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q4 2015 was Foresite Capital Management II, an estimated $4.77M added.
- The largest Orexigen Therapeutics, Inc. seller in Q4 2015 was State Street, an estimated $24.1M sold.
Based on aggregated 13F filings for Q4 2015.